Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Stage IV EGFR Mutated Non-Small Cell Lung Cancer”

84 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 84 results

Large-scale testing (Phase 3)Study completedNCT02864251
What this trial is testing

Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 367
Post-approval studies (Phase 4)Study completedNCT02514174
What this trial is testing

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Who this might be right for
Carcinoma, Non-Small-Cell LungErbB Receptors
Boehringer Ingelheim 25
Large-scale testing (Phase 3)Looking for participantsNCT07155187
What this trial is testing

Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
AbbVie 430
Testing effectiveness (Phase 2)Looking for participantsNCT06947694
What this trial is testing

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases

Who this might be right for
NSCLC Stage IV Without EGFR/ALK Mutation
Xinqiao Hospital of Chongqing 427
Post-approval studies (Phase 4)Study completedNCT03853551
What this trial is testing

Osimertinib Study in Indian Patients

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Testing effectiveness (Phase 2)UnknownNCT01131429
What this trial is testing

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Neoplasms, LungCarcinoma, Non-Small Cell LungDrug Therapy+1 more
Chinese PLA General Hospital 60
Early research (Phase 1)Active Not RecruitingNCT05681780
What this trial is testing

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Who this might be right for
Non Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 13
Testing effectiveness (Phase 2)Ended earlyNCT02846792
What this trial is testing

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Who this might be right for
ALK Gene TranslocationEGFR Activating MutationRecurrent Non-Small Cell Lung Carcinoma+3 more
University of Washington 5
Large-scale testing (Phase 3)Ended earlyNCT02588261
What this trial is testing

ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Astellas Pharma Global Development, Inc. 530
Post-approval studies (Phase 4)Study completedNCT00608868
What this trial is testing

SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients

Who this might be right for
Non Small Cell Lung Carcinoma
AstraZeneca 156
Not applicableStudy completedNCT01124669
What this trial is testing

Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate

Who this might be right for
Lung Cancer
ECOG-ACRIN Cancer Research Group 80
Large-scale testing (Phase 3)Active Not RecruitingNCT02438722
What this trial is testing

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Who this might be right for
Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
SWOG Cancer Research Network 174
Large-scale testing (Phase 3)Ended earlyNCT04427072
What this trial is testing

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT02971501
What this trial is testing

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the BrainStage IV Lung Cancer AJCC v8
National Cancer Institute (NCI) 7
Not applicableStudy completedNCT03944265
What this trial is testing

Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer

Who this might be right for
Activating ALK Gene Mutation NegativeActivating EGFR Gene Mutation NegativeActivating ROS1 Gene Mutation Negative+5 more
Thomas Jefferson University 14
Not applicableUnknownNCT06154967
What this trial is testing

To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 20
Not applicableNot Yet RecruitingNCT06117644
What this trial is testing

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIA+1 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 30
Post-approval studies (Phase 4)Study completedNCT02208843
What this trial is testing

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07298148
What this trial is testing

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

Who this might be right for
NSCLC Stage IVEGFR Positive Non-small Cell Lung CancerEGFR-TKI Sensitizing Mutation
Peking University Cancer Hospital & Institute 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT04027647
What this trial is testing

Phase 2 Study of Dacomitinib in NSCLC

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IIICNSCLC Stage IV+2 more
National Cancer Centre, Singapore 118
Load More Results